Evidence map›Paper›PMID 27890934›Full record

ArticleLeukemia2017

EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia.

E Young, D Noerenberg, L Mansouri, V Ljungström, M Frick, L-A Sutton, S J Blakemore, J Galan-Sousa, K Plevova, P Baliakas and 33 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 52 citations in OpenAlex.

  1. Trial
  2. Review
  3. Chromatin Remodeling in Patient-Derived Colorectal Cancer Models.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
  4. Article
  5. Observational
  6. Article
  7. Review
  8. [Clonality relatedness and molecular characteristics of Richter transformation].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022
    Article
  9. Towards precision medicine in lymphoid malignancies.Journal of internal medicine · 2022
    Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

43 authors at 20 institutions in 11 countries.

E YoungDepartment of Immunology, Genetics, and Pathology, Science for Life Laboratory, Uppsala University, Sweden.
D NoerenbergDepartment of Hematology, Oncology, and Tumor Immunology, Charité, University Medical Center, Berlin, Germany.
L MansouriDepartment of Immunology, Genetics, and Pathology, Science for Life Laboratory, Uppsala University, Sweden.
V LjungströmDepartment of Immunology, Genetics, and Pathology, Science for Life Laboratory, Uppsala University, Sweden.
M FrickDepartment of Hematology, Oncology, and Tumor Immunology, Charité, University Medical Center, Berlin, Germany.
L-A SuttonDepartment of Immunology, Genetics, and Pathology, Science for Life Laboratory, Uppsala University, Sweden.
S J BlakemoreCancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
J Galan-SousaDepartment of Hematology, Oncology, and Tumor Immunology, Charité, University Medical Center, Berlin, Germany.
K PlevovaCentral European Institute of Technology, Masaryk University and University Hospital Brno, Brno, Czech Republic.
P BaliakasDepartment of Immunology, Genetics, and Pathology, Science for Life Laboratory, Uppsala University, Sweden.
D RossiDivision of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy.
R CliffordOxford National Institute for Health Research Biomedical Research Centre and Department of Oncology, University of Oxford, Oxford, UK.
D Roos-WeilINSERM, U1170, Institut Gustave Roussy, Villejuif, France.
V NavrkalovaCentral European Institute of Technology, Masaryk University and University Hospital Brno, Brno, Czech Republic.
B DörkenDepartment of Hematology, Oncology, and Tumor Immunology, Charité, University Medical Center, Berlin, Germany.
C A SchmittDepartment of Hematology, Oncology, and Tumor Immunology, Charité, University Medical Center, Berlin, Germany.
K E SmedbyDepartment of Medicine Solna, Clinical Epidemiology Unit, Karolinska Institutet, and Hematology Center, Karolinska University Hospital, Stockholm, Sweden.
G JuliussonDepartment of Laboratory Medicine, Stem Cell Center, Lund University, Lund, Sweden.
B GiacopelliDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
J S BlachlyDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
C BelessiHematology Department, General Hospital of Nikea, Piraeus, Greece.
P PanagiotidisFirst Department of Propaedeutic Medicine, School of Medicine, University of Athens, Athens, Greece.
N ChiorazziKarches Center for Chronic Lymphocytic Leukemia Research, The Feinstein Institute for Medical Research, Manhasset, New York, USA.ORCID 0000-0003-1023-6650
F DaviLaboratory of Hematology and Universite Pierre et Marie Curie, Hopital Pitie-Salpetriere, Paris, France.
A W LangerakDepartment of Immunology, Laboratory for Medical Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
D OscierDepartment of Molecular Pathology, Royal Bournemouth Hospital, Bournemouth, UK.
A SchuhOxford National Institute for Health Research Biomedical Research Centre and Department of Oncology, University of Oxford, Oxford, UK.
G GaidanoDivision of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy.
P GhiaUniversità Vita-Salute San Raffaele, Milan, Italy.ORCID 0000-0003-3750-7342
W XuDepartment of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center For Cancer Personalized Medicine, Nanjing, China.
L FanDepartment of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center For Cancer Personalized Medicine, Nanjing, China.
O A BernardINSERM, U1170, Institut Gustave Roussy, Villejuif, France.
F Nguyen-KhacLaboratory of Hematology and Universite Pierre et Marie Curie, Hopital Pitie-Salpetriere, Paris, France.
L RassentiDivision of Hematology/Oncology, Department of Medicine, University of California at San Diego/Moores Cancer Center, La Jolla, CA, USA.
J LiDepartment of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center For Cancer Personalized Medicine, Nanjing, China.
T J KippsDivision of Hematology/Oncology, Department of Medicine, University of California at San Diego/Moores Cancer Center, La Jolla, CA, USA.
K StamatopoulosDepartment of Immunology, Genetics, and Pathology, Science for Life Laboratory, Uppsala University, Sweden.
S PospisilovaCentral European Institute of Technology, Masaryk University and University Hospital Brno, Brno, Czech Republic.
T ZenzDepartment of Molecular Therapy in Haematology and Oncology (G250) and Department of Translational Oncology, National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ), Heidelberg, Germany.
C C OakesDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
J C StreffordCancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
R RosenquistDepartment of Immunology, Genetics, and Pathology, Science for Life Laboratory, Uppsala University, Sweden.
F DammDepartment of Hematology, Oncology, and Tumor Immunology, Charité, University Medical Center, Berlin, Germany.
Uppsala University · SECharité - Universitätsmedizin Berlin · DECentral European Institute of Technology · CZJiangsu Province Hospital · CNThe Ohio State University · USGerman Cancer Research Center · DEInserm · FRNational Institute for Health Research · GBSorbonne Université · FRUniversità degli Studi del Piemonte Orientale “Amedeo Avogadro” · ITUniversity of California San Diego · USUniversity of Southampton · GBErasmus MC · NLFeinstein Institute for Medical Research · USGeneral Hospital of Nikea · GRKarolinska University Hospital · SELund University · SENational and Kapodistrian University of Athens · GRRoyal Bournemouth Hospital · GBVita-Salute San Raffaele University · IT

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Tissue CoreP01CA081534 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KIPPS, THOMAS J · 2000 to 2016
$59.5M
NCI NIH HHS P01 CA081534NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

Recurrent mutations within EGR2 were recently reported in advanced-stage chronic lymphocytic leukemia (CLL) patients and associated with a worse outcome. To study their prognostic impact, 2403 CLL patients were examined for mutations in the EGR2 hotspot region including a screening (n=1283) and two validation cohorts (UK CLL4 trial patients, n=366; CLL Research Consortium (CRC) patients, n=490). Targeted deep-sequencing of 27 known/postulated CLL driver genes was also performed in 38 EGR2-mutated patients to assess concurrent mutations. EGR2 mutations were detected in 91/2403 (3.8%) investigated cases, and associated with younger age at diagnosis, advanced clinical stage, high CD38 expression and unmutated IGHV genes. EGR2-mutated patients frequently carried ATM lesions (42%), TP53 aberrations (18%) and NOTCH1/FBXW7 mutations (16%). EGR2 mutations independently predicted shorter time-to-first-treatment (TTFT) and overall survival (OS) in the screening cohort; they were confirmed associated with reduced TTFT and OS in the CRC cohort and independently predicted short OS from randomization in the UK CLL4 cohort. A particularly dismal outcome was observed among EGR2-mutated patients who also carried TP53 aberrations. In summary, EGR2 mutations were independently associated with an unfavorable prognosis, comparable to CLL patients carrying TP53 aberrations, suggesting that EGR2-mutated patients represent a new patient subgroup with very poor outcome.

Indexed as

MutationAdultAgedEarly Growth Response Protein 2FemaleGenes, p53HumansLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedProportional Hazards ModelsEarly Growth Response Protein 2EGR2 protein, human

Identifiers

PMID27890934
PMCPMC7001738
OpenAlexW2558509262

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.